Abstract
Background: Efavirenz, a first line anti-retroviral drug has variable bioavailability owing to its limited aqueous solubility. Piperine, a bioavailability enhancer has been often used to enhance the bioavailability of many drugs. Objective: The present study was aimed to investigate the possibility of improving the bioavailability of efavirenz using piperine. Methods: Two doses of efavirenz 9.33 mg/kg and 28 mg/kg which corresponded to 200 and 600 mg/kg of human dose were selected. Single oral dose of efavirenz and piperine co administration was given to rabbit and at fixed time interval drug blood concentration was estimated by HPLC. Pharmacokinetic parameters of efavirenz and piperine co administration were determined. Results: Efavirenz 9.33 mg/kg co administration with piperine 20.8 mg/kg increased area under the curve significantly at p<0.01 and Cmax at p<0.05 compared to efavirenz control (9.33 mg/kg). The relative bioavailability of efavirenz and piperine co-administration was found to be 149.08%, i.e., higher than efavirenz control. T1/2 of piperine co-administration was also increased significantly at p<0.05 compared to efavirenz control. Tmax of piperine co-administration was found to be 0.5 h, followed by efavirenz control i.e., 1 h. Co-administration of efavirenz (28 mg/kg) with piperine (20.8 mg.kg) significantly increased AUC and Cmax at p<0.001 compared to efavirenz control (28 mg/kg). The relative bioavailability of Piperine co-administration was found to be 158.92%, higher than efavirenz control. There was significant increase in T1/2 of piperine co-administration at p<0.01 compared to efavirenz control. Tmax of piperine co-administration and efavirenz were found to be same i.e., 1 h. Conclusion: Based on the results it can be concluded that piperine co-administration significantly increases the oral exposure of efavirenz. Bioavailability of efavirenz with piperine was found to be higher than efavirenz control.
Highlights
Bioavailability enhancers concept is derived from traditional system of Ayurveda
The mean plasma concentration – time profile of efavirenz at dose 9.33 and 28 mg/kg with and without piperine were characterized in rabbit and illustrated in Figures 1 and 2
Cmax with piperine co-administration increased significantly at p
Summary
Bioavailability enhancers concept is derived from traditional system of Ayurveda. There action was first documented by Bose in 1929 where the anti-asthmatic properties of Adhatoda vasika leaves were enhanced by long pepper. Oral Bioavailability Enhancement of Efavirenz using Piperine coadministration in Experimental Rabbits. Results: Efavirenz 9.33 mg/kg co administration with piperine 20.8 mg/kg increased area under the curve significantly at p
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Pharmaceutical Research Science & Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
